Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A comprehensive overview of the state-of-the-art in the evaluation and treatment of male infertility, a problem with diverse etiology that affects 10% of couples. Including several simple algorithms to guide the physician's management decisions, this Review takes an evidence-based medicine approach to provide comment on the relevant merit of conservative and assisted-reproduction strategies.
The management of erectile dysfunction has been transformed since the first oral phosphodiesterase type 5 (PDE-5) inhibitor sildenafil (Viagra®) was approved in the late 1990s. The PDE-5 inhibitors developed subsequently (tadalafil [Cialis®] and vardenafil [Levitra®]) differ in important ways from their predecessor. Here, Alberto Briganti and his colleagues compare and contrast the pharmacokinetics, pharmacodynamics, safety and efficacy of these three drugs.
Up to half of patients with VHL develop malignant renal lesions. Urologists handling these cases are faced with the challenge of optimizing control of often bilateral multifocal tumors while maximizing preservation of kidney function. Robert Grubb and colleagues assess the relative merits of different management strategies, and present the molecular processes underlying VHL that might be targeted by new treatments.
